Healthcare company EZZ Life Science Holdings (ASX:EZZ) has announced plans to diversify into genomics and precision nutrition after its initial foray into over-the-counter nutritional supplements last year.
Acting CEO and co-founder Mark Chen said the company hopes to emerge as a major participant in the genomics sector.
“Over the course of this year, our brand products have included a range of health supplements, and our future product development pipeline will increasingly include healthcare solutions based on genomic research,” he said.
EZZ is increasing its interest in HPV (a viral infection), Helicobacter pylori (a gastrointestinal bacterium), weight loss and longevity because these conditions can be addressed through genetic diagnosis and careful (or customized) nutrition.
Genomics focuses on the study of genes as well as the proteins needed to read and maintain DNA, as well as the many particles that help store it and give it shape.
The genome revolution has been driven by genome sequencing technology that reads DNA and could be useful in identifying inherited disorders, characterizing genetic mutations that drive cancer development, or tracking disease outbreaks.
Genomics has been scientifically proven to prevent, manage and treat some diseases.
Applications of genetic technologies provide opportunities to improve healthcare across fields including genetic diagnosis, personalized medicine, and gene therapy.
Studies have shown that genetic testing can provide insights into how a person’s body functions, and what nutritional factors are best for an individual’s health needs.
Investing in the genome industry
The field of genomics has advanced faster than any other discipline in the life sciences, with innovation making a huge difference in terms of gene editing, cancer detection, DNA sequencing, and agricultural biology.
An increase in government funding for genome research has led to market growth. One of the most significant global developments in the region has been the Human Genome Project – an international collaborative research program aimed at the full mapping and understanding of all genes in the human body.
Led by the US government, the project began in 1990 and culminated in the first complete sequencing of the human genome in 2000.
The project is believed to have launched the field of genomics, transformed medicine and led to the emergence of the modern biotechnology industry.
In 2018, the US National Institute of Health provided $28.6 million through the All Of Us Research Program to establish three genome centers in the country.
Investors have also shown a growing interest in genomics stocks in the past decade as evidenced by the MSCI ACWI Genomic Innovation Index, which has outperformed the benchmark by nearly 50% since 2013. The index includes about 250 companies engaged in genomic innovation and has returned more than 43% in 2020. lonliness.
The global genomics market is expected to reach $74.6 billion by 2025 from $31.3 billion in 2020, with a compound annual growth rate (CAGR) of 19%.
Key factors behind the growth include increased government funding to support genomics projects, increased applications of Next Generation Sequencing (NGS) in cancer research, more areas of application of genomics, and the entry of new players and start-ups to the market.
“Today, we can map anyone’s DNA in just a few hours for about $1,000 [but] Three years from now, [we expect] The cost will come down to about $100, Chen said.
“By 2025, 100 million genomes are expected to have been sequenced…and when that happens, it will open up a whole new world of understanding and genomics will officially become mainstream.”